New Needle for Two-Needle Hemodialysis
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 4/2/2016 |
| Start Date: | August 2011 |
| End Date: | September 2012 |
| Contact: | Pedro A Jose, MD, PhD |
| Email: | pjose@cnmc.org |
| Phone: | 202-476-5715 |
Our preliminary studies have demonstrated that an innovative new design of the hemodialysis
venous needle (the needle that returns the cleaned blood from the hemodialysis filter to the
patient) with three jets is superior to the standard venous needle because it decreases the
velocity and turbulence of the blood when compared with the standard venous needle, it is
more efficient in the removal of toxins from the blood, and it is safe and effective. More
importantly, our preliminary studies suggested that the new needle causes less damage to the
dialysis vascular access and to circulating blood cells and less inflammation and oxidative
stress. These will decrease medical complications, the high cost of care and death in
dialysis patients. The current study will corroborate the finding of previous studies.
venous needle (the needle that returns the cleaned blood from the hemodialysis filter to the
patient) with three jets is superior to the standard venous needle because it decreases the
velocity and turbulence of the blood when compared with the standard venous needle, it is
more efficient in the removal of toxins from the blood, and it is safe and effective. More
importantly, our preliminary studies suggested that the new needle causes less damage to the
dialysis vascular access and to circulating blood cells and less inflammation and oxidative
stress. These will decrease medical complications, the high cost of care and death in
dialysis patients. The current study will corroborate the finding of previous studies.
Inclusion Criteria:(1) end stage renal disease receiving hemodialysis in an ambulatory
outpatient dialysis facility (2) male or female, (3) ages 18-80, (4) arterio-venous graft
or AV fistula as vascular access,
Exclusion Criteria:patients with fever, infection, inflammation or malignancy will be
excluded
We found this trial at
1
site
Click here to add this to my saved trials
